Roivant Sciences Ltd. — Director's Dealing 2026

Feb 11, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2026-02-09

Reporting Person: Sukhatme Mayukh (Director, President & CIO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-09	Common Shares	M	651558	$12.68	Acquired	19488105	Direct
2026-02-09	Common Shares	S	339441	$26.47	Disposed	19148664	Direct
2026-02-09	Common Shares	J	312117	$26.47	Disposed	18836547	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-09	Stock Option (Right to Buy)	$12.68	M	651558	Disposed	2026-03-31	Common Shares (651558)	Direct

Footnotes

F1: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

F2: These Common Shares were sold in multiple transactions at prices ranging from $25.92 to $26.78, inclusive.

F3: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

F4: Award of stock options to purchase Common Shares that is fully vested.